Company intelligence / Profile preview

Anmai Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Lead asset EMB-01 is the world's first EGFR/c-MET bispecific antibody in Phase II trials for colorectal cancer, showing potential to overcome resistance seen in single-target therapies and undergoing both monotherapy and combination chemo research; additional T-cell engager assets (EMB-06, EMB-07) advancing for BCMA/CD3 and ROR1/CD3 targets in cancer and immune indications

Therapeutic areas: OncologyImmunology
Modalities: Bispecific monoclonal antibodyT cell engagerMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Anmai Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anmai Biotechnology.

Explore the full profile